Arkolith/Insider Trading/NTLA/Form 4

Schultes Birgit C

EVP, Chief Scientific OfficerIntellia Therapeutics, Inc. (NTLA) · full profile →Form 4 · filed Jan 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$78K
Net Open-Market Flow
-$78K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 5, 2026Sell(S)9K$9.21$78K99K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-006292) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Intellia Therapeutics, Inc.

Build

Ask your agent about NTLA insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-006292"
Ask your agent
Use Arkolith to summarize insider buying and selling at Intellia Therapeutics, Inc.
over the last 90 days and cite the filings.